ADDISON, Texas, Feb. 23, 2012 /PRNewswire/ -- ULURU
Inc. (NYSE AMEX: ULU),announced today that an Australian
Register of Therapeutic Goods Certificate has been issued by the
Therapeutic Goods Administration approving the marketing of
Altrazeal® in Australia.
Commenting on the approval in Australia, Kerry P.
Gray, President and CEO of ULURU, stated, "This is another
important milestone in the worldwide commercialization of
Altrazeal®. Strategically this is an important market as the
world's largest wound research program is currently being conducted
at the Wound Management Innovation Cooperation Research Centre in
Australia. This centre's focus is the development of
clinically and cost effective treatment regimens for the management
of chronic wounds. Gaining the support of this influential
group could have significant global implications for the marketing
of Altrazeal®. It is anticipated that the initial Altrazeal®
orders for Australia will occur in
the next thirty days. Also, marketing approval in
New Zealand is anticipated to
occur in the next thirty days."
The timing of this approval is beneficial as the major
Australian wound care meeting, the Australian Wound Management
Association Conference, will be held in Sydney, Australia on March 18-21, 2012. It is anticipated that
over 1,000 delegates from Australia and New
Zealand will be attending this conference. The
conference will enable pre-marketing launch activities to be
conducted and provide maximum exposure for Altrazeal® to the most
important wound treatment healthcare professionals from both
countries.
In Australia and New Zealand approximately 2.5% of the
population, or 700,000 patients, suffer from chronic wounds, with
80% of these wounds caused by cardiovascular disease, endocrine
disorders (including diabetes), and infection. With the
increase in cardiovascular disease, obesity, and the aging
population, it is anticipated that the wound care market will
double in size over the next five to seven years and the cost of
treating chronic wounds will exceed $1.0
billion annually.
Mr. Gray continued, "The Australian state government's strategic
initiatives in wound care are focused on cost effective clinical
endpoints and patient health and wellbeing. The
pharmaco-economic benefits offered by Altrazeal® could enable rapid
market penetration in the Australian market."
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company
focused on the development of a portfolio of wound management and
oral care products to provide patients and consumers improved
clinical outcomes through controlled delivery utilizing its
innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal
delivery system. For further information about ULURU Inc.,
please visit our website at www.uluruinc.com. For further
information about Altrazeal®, please visit www.Altrazeal.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended. These statements are subject to
numerous risks and uncertainties, including but not limited to our
belief that Altrazeal® will be a major competitor in the
wound care market, anticipated product launches in Australia and New
Zealand, the cost effectiveness and cost savings of
Altrazeal® in healing chronic wounds, the size of the
wound care market and the cost of treating chronic wounds in
Australia and New Zealand, the world's largest wound
research program is currently being conducted at the Wound
Management Innovation Cooperation Research Centre in Australia, Altrazeal's clinical and economic
advantages, and Altrazeal's ability to penetrate the Australian
wound care market, and to the risk factors detailed in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2010, and other reports
filed by us with the Securities and Exchange Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
SOURCE ULURU Inc.